AbClon Secures US Patent for CD30-Targeted CAR-T Technology
Joint Research Success with UPenn
"Efforts Underway for Technology Transfer Between the Two Institutions"
AbClon announced on July 6 that its 'core technology related to CD30-targeting chimeric antigen receptor T-cell (CAR-T) therapy,' developed through joint research with the University of Pennsylvania (UPenn), recently received final patent registration from the United States Patent and Trademark Office (USPTO).
AbClon stated, "This patent is a result of joint research with UPenn, a world-renowned institution in this field that developed the world's first CAR-T therapy, Kymriah. Being listed as co-patent holders demonstrates the technical sophistication and global credibility of our innovation, now officially recognized at the highest level."
Appclon announced that its 'CD30-targeting chimeric antigen receptor T-cell (CAR-T) therapy-related core technology,' developed through joint research with the University of Pennsylvania (UPenn), has recently received final patent registration from the United States Patent and Trademark Office (USPTO). Appclon
View original imageThis patent covers a novel antibody that precisely targets the CD30 protein, which is distinctly overexpressed on the surface of cancer cells in patients with malignant lymphomas, including Hodgkin lymphoma, as well as next-generation CAR-T therapy technology applying this antibody. Since CD30 is expressed at extremely low levels in normal cells, targeting it enables an ideal treatment approach that powerfully and selectively destroys cancer cells while minimizing damage to normal cells.
In particular, the company noted that this antibody was engineered to recognize a new epitope (antigen binding site) that is completely different from those targeted by existing CD30 antibodies. As a result, it could offer a new paradigm in treatment alternatives for refractory cancer patients who fail to respond to, or have developed resistance against, current therapies.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A representative from AbClon stated, "Our close collaboration with UPenn, home to some of the world’s top CAR-T researchers, has been validated for originality and exclusive rights through the United States Patent and Trademark Office. Starting with this global intellectual property acquisition, we will accelerate the research and development of our CD30 CAR-T pipeline, while also working to realize the technology transfer (L/O) currently under discussion between the two institutions."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.